Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by First Light Asset Management LLC

First Light Asset Management LLC lessened its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 5.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 383,310 shares of the company’s stock after selling 23,038 shares during the period. Kymera Therapeutics makes up 1.5% of First Light Asset Management LLC’s investment portfolio, making the stock its 21st largest holding. First Light Asset Management LLC owned 0.59% of Kymera Therapeutics worth $15,421,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. lifted its stake in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after purchasing an additional 270 shares during the period. KBC Group NV lifted its stake in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after purchasing an additional 752 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Kymera Therapeutics by 95.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company’s stock valued at $194,000 after purchasing an additional 2,350 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock valued at $198,000 after purchasing an additional 406 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Kymera Therapeutics in the fourth quarter valued at about $251,000.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Citigroup assumed coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 price objective for the company. Stephens restated an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Finally, HC Wainwright raised their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $56.36.

Kymera Therapeutics Trading Down 0.9 %

NASDAQ:KYMR opened at $33.26 on Monday. The stock has a 50 day moving average of $29.89 and a 200-day moving average of $38.54. The firm has a market capitalization of $2.16 billion, a PE ratio of -14.21 and a beta of 2.22. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other news, COO Jeremy G. Chadwick sold 1,383 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the transaction, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. The trade was a 3.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock valued at $324,567 in the last ninety days. Company insiders own 15.82% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.